ESMO: Daiichi, Merck power ovarian cancer ADC toward pivotal test after passing phase 2
Daiichi Sankyo and Merck & Co. have reported midphase ovarian cancer data, clearing the partners to advance the antibody-drug conjugate into the phase 3 part of the trial. The phase…